Table 1. Genomic alterations observed in PMNSGCT versus features from gonadal primary GCT.
a
GA in PMNSGCT with sarcomatous malignant transformation (n = 11): RAS‐RAF pathway: 4/11 (36.4%); TP53 pathway: 10/11 (90.9%); Cell‐cycle pathway: 2/11 (18.2%); RTK pathway: 1/11 (9.1%); PI3K pathway: 6/11 (54.5%); DDR pathway: 0; TMB (median): 1.9 mut/Mb (IQR: 1.5–3.9).
b
Fisher's exact test or t test, where appropriate; reference comparison: PMNSGCT versus NS.
Abbreviations: DDR, DNA‐damage response and repair genes; GA, genomic alterations; GCT, germ cell tumors; IQR, interquartile range; MSI, microsatellite instability; Mut, mutations; NS, testicular nonseminomas; PMNSGCT, primary mediastinal nonseminomatous germ cell tumors; SD, standard deviation; Sem, testicular seminomas; TMB, tumor mutational burden.